Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in CRVS held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 7.2M | $107.0M | 0.0% | 8.521% | 1.98% |
| 2 | BlackRock, Inc. | 7.1M | $106.7M | +15.9% | 8.489% | 0.00% |
| 3 | STATE STREET CORP | 4.5M | $66.8M | +25.5% | 5.321% | 0.00% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3M | $49.2M | +1.8% | 3.916% | 0.00% |
| 5 | ADAMS STREET PARTNERS LLC | 3.3M | $48.9M | 0.0% | 3.895% | 11.06% |
| 6 | Vivo Capital, LLC | 2.8M | $41.9M | 0.0% | 3.337% | 3.83% |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 2.7M | $40.8M | +17.8% | 3.248% | 0.01% |
| 8 | PERCEPTIVE ADVISORS LLC | 2.7M | $39.9M | +16.4% | 3.172% | 0.60% |
| 9 | Deep Track Capital, LP | 2.5M | $37.2M | +0.0% | 2.963% | 0.54% |
| 10 | BRAIDWELL LP | 2.1M | $31.8M | +21.3% | 2.529% | 1.18% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1.9M | $27.7M | +8.2% | 2.204% | 0.00% |
| 12 | Foresite Capital Management VI LLC | 1.8M | $27.4M | 0.0% | 2.178% | 4.26% |
| 13 | GOLDMAN SACHS GROUP INC | 1.6M | $23.6M | +2.3% | 1.875% | 0.00% |
| 14 | Hood River Capital Management LLC | 1.6M | $23.5M | +17.7% | 1.869% | 0.17% |
| 15 | MORGAN STANLEY | 1.3M | $20.1M | -46.2% | 1.599% | 0.00% |
| 16 | Boxer Capital Management, LLC | 1.1M | $16.4M | 0.0% | 1.308% | 1.24% |
| 17 | Catalio Capital Management, LP | 1.1M | $16.1M | +21.2% | 1.285% | 3.03% |
| 18 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.1M | $15.7M | +36.7% | 1.249% | 0.00% |
| 19 | MILLENNIUM MANAGEMENT LLC | 1.0M | $15.7M | +21.0% | 1.246% | 0.01% |
| 20 | CITADEL ADVISORS LLC | 1.0M | $15.6M | +14.3% | 1.240% | 0.00% |
| 21 | VANGUARD PORTFOLIO MANAGEMENT LLC | 815K | $12.2M | +21.6% | 0.969% | 0.00% |
| 22 | TWO SIGMA INVESTMENTS, LP | 785K | $11.7M | +45.4% | 0.934% | 0.01% |
| 23 | BANK OF AMERICA CORP /DE/ | 758K | $11.3M | +219.7% | 0.901% | 0.00% |
| 24 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 750K | $11.2M | 0.0% | 0.892% | 0.02% |
| 25 | Eversept Partners, LP | 748K | $11.2M | β | 0.889% | 0.58% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in CRVS β a direct measure of their conviction.
Filings activity in CRVS during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 172 | +6.2% | 86.35% | +1.32 pp | $1.03B | +2.7% |
| Q1 2026 | 162 | +31% | 85.03% | +21.10 pp | $1000M | +173% |
| Q4 2025 | 124 | +18% | 63.93% | +7.62 pp | $367M | +20% |
| Q3 2025 | 105 | +13% | 56.31% | +0.12 pp | $306M | +86% |
| Q2 2025 | 93 | +9.4% | 56.19% | +4.78 pp | $164M | +49% |
| Q1 2025 | 85 | +0.0% | 51.41% | 5.24 pp | $110M | 46% |
| Q4 2024 | 85 | +39% | 56.65% | +8.36 pp | $204M | +28% |
| Q3 2024 | 61 | β | 48.29% | β | $159M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Latest Form 4 transactions by company officers and directors. Insider buys are widely viewed as a key fundamental indicator because executives are risking personal capital.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 11, 2026 | Moore David Scott | Buy | 22K | $11.53 | $250K |
Quick answers to the most common questions about buying CRVS stock.
Based on Q2 2026 13F filings, institutional ownership of Corvus Pharmaceuticals, Inc. stands at 86.4%, held across 172 reporting institutions.
ORBIMED ADVISORS LLC is the largest reported institutional holder of CRVS, with approximately 7,165,006 shares worth $0.11B as of Q2 2026.
Yes β 4 widely-followed marquee investors appear among the top 25 institutional holders of CRVS, including SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP.
Our composite Smart Money Score for CRVS is 73 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
35 institutions opened new positions in CRVS during Q2 2026, while 28 fully exited. 103 added to existing positions and 30 trimmed.
CRVS institutional ownership rose by 1.32 percentage points quarter-over-quarter, with a net change of +10 holders.
The top 10 institutions account for 55.5% of all reported 13F value in CRVS, and the top 25 account for 80.8%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Corvus Pharmaceuticals, Inc. (CRVS) Institutional Ownership